Bristol Myers Squibb - News
WEBSep 10, 2024 — Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
WEBMar 18, 2024 — Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications. PRINCETON, N.J.-- (BUSINESS WIRE)-- …
Bristol Myers Squibb Strengthens and Diversifies Oncology …
WEBOct 8, 2023 — Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising clinical assets that complement its oncology pipeline and are strong candidates for single agent development and combination strategies.
Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth …
WEBFeb 2, 2024 — Bristol Myers Squibb posted fourth quarter revenues of $11.5 billion, an increase of 1% both on a reported and when adjusted for foreign exchange basis, primarily due to higher sales of new product portfolio, as well as Eliquis and Opdivo, partially offset by lower sales of Revlimid.
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
WEBDec 22, 2023 — Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics. Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety. KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in …
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
WEBDec 26, 2023 — Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio. Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb’s Leading Oncology Franchise. Lead Program, RYZ101, in …
Bristol Myers Squibb - Bristol Myers Squibb Announces First …
WEBDec 12, 2022 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results and presentation of new research from its multiple myeloma portfolio across targets and molecular approaches at the 64 th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring the company’s commitment ...
Bristol Myers Squibb Completes Acquisition of Turning Point ...
WEBAug 17, 2022 — Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.
Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth …
WEBFeb 2, 2023 — Bristol Myers Squibb posted revenues of $11.4 billion, a decrease of 5%, driven by recent LOE products (primarily Revlimid) and foreign exchange impacts, partially offset by in-line products (primarily Opdivo) and our new product portfolio (primarily Opdualag and Abecma). When adjusted for foreign exchange, revenues decreased 1%.
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
WEBJun 3, 2022 — Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to …